Pfizer’s BRAFTOVI regimen doubles response rates for metastatic colorectal cancer
Pfizer Inc. has unveiled compelling findings from the Phase 3 BREAKWATER trial, highlighting the efficacy of its BRAFTOVI (encorafenib) combination regimen in treating metastatic colorectal ... Read More
Array BioPharma’s new colorectal cancer treatment gains breakthrough therapy designation from FDA
Array BioPharma has achieved a significant regulatory milestone as its innovative combination therapy for metastatic colorectal cancer (mCRC) has been granted breakthrough therapy designation by ... Read More